Sutro Biopharma: Recycling Past Data Ahead Of The Readout, Sell

Sutro Biopharma underwent major restructuring, including management changes and layoffs. Read why I rate STRO stock a Strong ...
Seeking Alpha

Week In Review: Multitude Out-Licenses Tissue Factor ADC To Adcendo In $1 Billion Deal

Multitude Therapeutics out-licensed global rights (ex-Greater China) for its Tissue Factor ADC to Denmark’s Adcendo in a $1 billion agreement. Huadong Pharmaceutical acquired rights for two immune ...
ascopubs.org

Expression of tissue factor (TF) in penile squamous cell carcinoma (PSCC) and enrichment in HPV-negative cases.

EPIC-B: Phase II trial of cemiplimab as first-line treatment in advanced penile carcinoma. Progressive T cell exhaustion and predominance of aging tissue associated macrophages with advancing disease ...
BioWorld

Sutro Biopharma unveils best-in-class anti-tissue factor ADC

Tissue factor (TF), a transmembrane protein overexpressed in tumors such as cervical, head and neck, NSCLC, and pancreatic cancers, initiates the extrinsic coagulation pathway under normal ...
BioWorld

Adcendo licenses rights to Multitude’s ADC targeting tissue factor

Adcendo ApS and Multitude Therapeutics Inc. have signed a licensing agreement for the development of a highly differentiated antibody-drug conjugate (ADC) targeting tissue factor, designated ADCE-T02.